



October 6, 2015

## **MacroGenics to Host 2015 R&D Day**

**--Company to provide in-depth review of its antibody-based technology platforms and broad portfolio of therapeutics being developed to treat cancer, autoimmune disorders and infectious diseases**

ROCKVILLE, Md., Oct. 06, 2015 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases, today announced that it will host a live webcast of its 2015 R&D Day for investors and analysts on Tuesday, October 13, 2015, in New York City. The webcast of the company's presentation and Q&A will begin at 8:30 am ET and is expected to conclude at 12:00 pm ET.

A link to the live webcast can be accessed by visiting the Events & Presentation page of the company's website at <http://ir.macrogenics.com/events.cfm>. In addition, a replay of the event will be posted on MacroGenics' website after the event and will be available for at least 45 days following the event.

### **About MacroGenics, Inc.**

MacroGenics is a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, as well as autoimmune disorders and infectious diseases. MacroGenics generates its pipeline of product candidates from its proprietary suite of next-generation antibody-based technology platforms. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the company's website at [www.macrogenics.com](http://www.macrogenics.com). MacroGenics is a registered trademarks of MacroGenics, Inc.

### **Cautionary Note on Forward-Looking Statements**

Any statements in this press release about future expectations, plans and prospects for MacroGenics, Inc. (the "Company"), including statements about the Company's strategy, future operations, clinical development of the Company's therapeutic candidates, milestone or opt-in payments from the Company's collaborators, the Company's anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company's product candidates and other risk factors described in the Company's filings with the Securities and Exchange Commission. In addition, the forward-looking statements included in this press release represent the Company's views as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company's views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date hereof.

Jim Karrels, Senior Vice President, CFO

MacroGenics, Inc.

1-301-251-5172, [info@macrogenics.com](mailto:info@macrogenics.com)

Karen Sharma, Vice President

MacDougall Biomedical Communications

1-781-235-3060, [ksharma@macbiocom.com](mailto:ksharma@macbiocom.com)

Source: MacroGenics, Inc.

News Provided by Acquire Media